Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Results for the second quarter were a bit better than expected. Non-GAAP earnings were $2.13 per share, better than the $2.02 ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

The Gardasil human papillomavirus virus vaccine remains Merck’s second best-selling drug behind cancer treatment Keytruda.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

Merck’s Gardasil generated $1.2 billion in revenue last year, while Cervarix brought in $812 million for London-based Glaxo.